Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Neurogenetics ; 6(3): 127-33, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16086184

RESUMEN

Major depressive disorder (MDD) is a mood disorder with a significant heritable component. Structural neuronal impairment has been considered to be implicated in MDD, as it leads to brain morphological alterations such as hippocampal atrophy. The Gem interacting protein, GMIP, is a novel Rho GTPase-activating protein known to play important roles in neurite growth and axonal guidance. We examined the GMIP gene for possible association in a Japanese sample of 164 patients with MDD and 164 controls matched for sex. We found a significant association with MDD for one single nucleotide polymorphism (SNP) (-525G/A) located on the 5'-upstream region of the GMIP gene (p=0.039, odds ratio 1.66, 95% CI 1.05-2.69) and stronger evidence for association in a multimarker haplotype analysis (p=0.004). We then performed a promoter-luciferase reporter assay; the promoter activity for -525A allele, which was in excess in the MDD patients, was significantly decreased compared with the -525G allele in transient transfection experiments using three types of cell lines. Our results suggest that genetic variations in the GMIP gene can confer susceptibility to MDD, and the associated promoter SNP might play a role in the transcriptional regulation of the GMIP gene. Further study needs to be undertaken to validate the association between the GMIP gene and MDD.


Asunto(s)
Trastorno Depresivo/genética , Proteínas Activadoras de GTPasa/genética , Polimorfismo de Nucleótido Simple , Secuencia de Bases , Encéfalo/patología , Cartilla de ADN , Trastorno Depresivo/patología , Frecuencia de los Genes , Genotipo , Hipocampo/patología , Humanos , Neuronas/patología , Reacción en Cadena de la Polimerasa , Eliminación de Secuencia
2.
Genomics ; 84(6): 1041-50, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15533721

RESUMEN

Mitochondrial dysfunction associated with mutant mitochondrial DNA (mtDNA) has been suggested in bipolar disorder, and comorbidity with neurodegenerative diseases was often noted. We examined the entire sequence of mtDNA in six subjects with bipolar disorder having comorbid somatic symptoms suggestive of mitochondrial disorders and found several uncharacterized homoplasmic nonsynonymous nucleotide substitutions of mtDNA. Of these, 3644C was found in 5 of 199 patients with bipolar disorder but in none of 258 controls (p = 0.015). The association was significant in the extended samples [bipolar disorder, 9/630 (1.43%); controls, 1/734 (0.14%); p = 0.007]. On the other hand, only 5 of 25 family members with this mutation developed bipolar disorder, of which 4 patients with 3644C had comorbid physical symptoms. The 3644T-->C mutation converts amino acid 113, valine, to alanine in the NADH-ubiquinone dehydrogenase subunit I, a subunit of complex I, and 113 valine is well conserved from Drosophila to 61 mammalian species. Using transmitochondrial cybrids, 3644T-->C was shown to decrease mitochondrial membrane potential and complex I activity compared with haplogroup-matched controls. According to human mitochondrial genome polymorphism databases, 3644C was not found in centenarians but was found in 3% of patients with Alzheimer disease and 2% with Parkinson disease. The result of modest functional impairment caused by 3644T-->C suggests that this mutation could increase the risk for bipolar disorder.


Asunto(s)
Trastorno Bipolar/genética , ADN Mitocondrial/genética , Células Híbridas/metabolismo , Mutación/genética , Adolescente , Adulto , Estudios de Casos y Controles , Complejo I de Transporte de Electrón/metabolismo , Femenino , Humanos , Células Híbridas/patología , Masculino , Potenciales de la Membrana , Persona de Mediana Edad , Mitocondrias/metabolismo , Linaje
3.
Clin Immunol ; 102(1): 12-8, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11781062

RESUMEN

We examined the feasibility of inducing local and systemic human immunodeficiency virus (HIV)-specific immune responses by rectal and vaginal application of an HIV-DNA vaccine. Mice were immunized with an HIV-DNA vaccine preparation via a rectal or vaginal route. After several applications, HIV-specific antibodies were detected in sera, fecal extract solutions, and vaginal washes, and these antibodies were potent in inhibiting the syncytium formation of a CD4-positive human T cell line by a cell line capable of inducing HIV-1 infection. Spleen cells from rectally and vaginally immunized mice showed antigen-mediated IFN-gamma-inducing activity. In addition, with rectal immunization, mononuclear cells from both the spleen and the regional lymph nodes of the rectal region were found to be potent at inducing a cytotoxic T lymphocyte response. These humoral and cell-mediated immune responses were enhanced by augmenting the vaccine with granulocyte-macrophage colony-stimulating factor-expressing plasmids or IL-12-expressing plasmid. Our results demonstrated that both rectal and vaginal immunization could induce systemic and mucosal immunity and that these responses were enhanced by the addition of the above cytokine-expressing plasmids.


Asunto(s)
Vacunas contra el SIDA/inmunología , VIH-1/inmunología , Vacunas de ADN/inmunología , Vacunas contra el SIDA/administración & dosificación , Administración Intravaginal , Administración Rectal , Animales , Femenino , Anticuerpos Anti-VIH/análisis , Inmunidad Celular , Interferón gamma/metabolismo , Ratones , Ratones Endogámicos BALB C , Membrana Mucosa/inmunología , Linfocitos T Citotóxicos , Vacunación , Vacunas de ADN/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA